{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:29:04Z","timestamp":1781522944681,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00340391"],"award-info":[{"award-number":["RS-2024-00340391"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-93962-x","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T16:44:31Z","timestamp":1741970671000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Early optical coherence tomography biomarkers for tailored frequency of intravitreal aflibercept in neovascular age-related macular degeneration"],"prefix":"10.1038","volume":"15","author":[{"given":"Gyeongsoo","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Yoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Byung","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoi Jong","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"93962_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong, W. L. et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob Health. 2, e106\u2013116 (2014).","journal-title":"Lancet Glob Health"},{"key":"93962_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl. J. Med. 355, 1419\u20131431 (2006).","journal-title":"N Engl. J. Med."},{"key":"93962_CR3","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin, D. F. et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl. J. Med. 364, 1897\u20131908 (2011).","journal-title":"N Engl. J. Med."},{"key":"93962_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown, D. M. et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116, 57\u201365e55 (2009).","journal-title":"Ophthalmology"},{"key":"93962_CR5","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier, J. S. et al. Intravitreal Aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119, 2537\u20132548 (2012).","journal-title":"Ophthalmology"},{"key":"93962_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ophtha.2015.09.018","volume":"123","author":"K Berg","year":"2016","unstructured":"Berg, K. et al. Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol: 2-Year results. Ophthalmology 123, 51\u201359 (2016).","journal-title":"Ophthalmology"},{"key":"93962_CR7","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1097\/IAE.0000000000003128","volume":"41","author":"P Mitchell","year":"2021","unstructured":"Mitchell, P. et al. Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: The aries study: A randomized clinical trial. Retina 41, 1911\u20131920 (2021).","journal-title":"Retina"},{"key":"93962_CR8","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji, M. et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-Week findings from ALTAIR: A randomized controlled trial. Adv. Ther. 37, 1173\u20131187 (2020).","journal-title":"Adv. Ther."},{"key":"93962_CR9","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","volume":"122","author":"CC Wykoff","year":"2015","unstructured":"Wykoff, C. C. et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 122, 2514\u20132522 (2015).","journal-title":"Ophthalmology"},{"key":"93962_CR10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","volume":"128","author":"CMG Cheung","year":"2021","unstructured":"Cheung, C. M. G. et al. Polypoidal choroidal vasculopathy: Consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific ocular imaging society PCV workgroup. Ophthalmology 128, 443\u2013452 (2021).","journal-title":"Ophthalmology"},{"key":"93962_CR11","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda, S. R. et al. Consensus definition for atrophy associated with age-related macular degeneration on OCT: Classification of atrophy report 3. Ophthalmology 125, 537\u2013548 (2018).","journal-title":"Ophthalmology"},{"key":"93962_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","volume":"126","author":"RH Guymer","year":"2019","unstructured":"Guymer, R. H. et al. Tolerating subretinal fluid in neovascular age-related macular degeneration treated with Ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology 126, 723\u2013734 (2019).","journal-title":"Ophthalmology"},{"key":"93962_CR13","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide, R. F. et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: Consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 127, 616\u2013636 (2020).","journal-title":"Ophthalmology"},{"key":"93962_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00417-008-0926-0","volume":"247","author":"C Lange","year":"2009","unstructured":"Lange, C., Feltgen, N., Junker, B., Schulze-Bonsel, K. & Bach, M. Resolving the clinical acuity categories hand motion and counting fingers using the freiburg visual acuity test (FrACT). Graefes Arch. Clin. Exp. Ophthalmol. 247, 137\u2013142 (2009).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"93962_CR15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","volume":"123","author":"S Sharma","year":"2016","unstructured":"Sharma, S. et al. Macular morphology and visual acuity in the 2 year of the comparison of age-related macular degeneration treatments trials. Ophthalmology 123, 865\u2013875 (2016).","journal-title":"Ophthalmology"},{"key":"93962_CR16","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.ophtha.2020.03.010","volume":"127","author":"U Schmidt-Erfurth","year":"2020","unstructured":"Schmidt-Erfurth, U., Vogl, W. D., Jampol, L. M. & Bogunovi\u0107, H. Application of automated quantification of fluid volumes to anti-VEGF therapy of neovascular age-related macular degeneration. Ophthalmology 127, 1211\u20131219 (2020).","journal-title":"Ophthalmology"},{"key":"93962_CR17","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","volume":"123","author":"SM Waldstein","year":"2016","unstructured":"Waldstein, S. M. et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials. Ophthalmology 123, 1521\u20131529 (2016).","journal-title":"Ophthalmology"},{"key":"93962_CR18","doi-asserted-by":"publisher","first-page":"100171","DOI":"10.1016\/j.xops.2022.100171","volume":"2","author":"SS Kar","year":"2022","unstructured":"Kar, S. S. et al. OCT-derived radiomic features predict anti-VEGF response and durability in neovascular age-related macular degeneration. Ophthalmol. Sci. 2, 100171 (2022).","journal-title":"Ophthalmol. Sci."},{"key":"93962_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12886-023-02780-0","volume":"23","author":"CY Tsai","year":"2023","unstructured":"Tsai, C. Y. et al. Baseline characteristics and treatment response predictive of nAMD outcomes with ranibizumab therapy in treatment-naive patients: The RACER subgroup analysis. BMC Ophthalmol. 23, 39 (2023).","journal-title":"BMC Ophthalmol."},{"key":"93962_CR20","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40123-020-00288-0","volume":"9","author":"CR Gill","year":"2020","unstructured":"Gill, C. R., Hewitt, C. E., Lightfoot, T. & Gale, R. P. Demographic and clinical factors that influence the visual response to anti-vascular endothelial growth factor therapy in patients with neovascular age-related macular degeneration: A systematic review. Ophthalmol. Ther. 9, 725\u2013737 (2020).","journal-title":"Ophthalmol. Ther."},{"key":"93962_CR21","doi-asserted-by":"crossref","unstructured":"Tsilimbaris, M. K., L\u00f3pez-G\u00e1lvez, M. I., Gallego-Pinazo, R., Margaron, P. & Lambrou, G. N. Epidemiological and clinical baseline characteristics as predictive biomarkers of response to anti-VEGF treatment in patients with neovascular AMD. J. Ophthalmol. 4367631 (2016).","DOI":"10.1155\/2016\/4367631"},{"key":"93962_CR22","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/08820538.2019.1620791","volume":"34","author":"JM Kim","year":"2019","unstructured":"Kim, J. M. et al. Responses of types 1 and 2 neovascularization in age-related macular degeneration to anti-vascular endothelial growth factor treatment: Optical coherence tomography angiography analysis. Semin Ophthalmol. 34, 168\u2013176 (2019).","journal-title":"Semin Ophthalmol."},{"key":"93962_CR23","doi-asserted-by":"crossref","unstructured":"R\u00fcbsam, A., Rau, S., Pilger, D., Zeitz, O. & Joussen, A. M. Early OCT angiography changes of macular neovascularization in patients with exudative AMD treated with brolucizumab in a real-world setting. J. Ophthalmol. 2659714 (2022). (2022).","DOI":"10.1155\/2022\/2659714"},{"key":"93962_CR24","doi-asserted-by":"crossref","unstructured":"Thomsen, A. K., Fasih-Ahmad, S., Sadda, S. & S\u00f8rensen, T. L. Initial treatment response can predict 1-year treatment outcomes in neovascular age-related macular degeneration treated according to the observe-and-plan regimen. Acta Ophthalmol. (2024).","DOI":"10.1111\/aos.16801"},{"key":"93962_CR25","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.oret.2016.12.004","volume":"1","author":"CC Wykoff","year":"2017","unstructured":"Wykoff, C. C. et al. Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-Year results of the TREX-AMD study. Ophthalmol. Retina  1, 314\u2013321 (2017).","journal-title":"Ophthalmol. Retina"},{"key":"93962_CR26","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1016\/j.ophtha.2020.01.029","volume":"127","author":"DF Martin","year":"2020","unstructured":"Martin, D. F. et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: 2-Year results. Ophthalmology 127, S135\u2013s145 (2020).","journal-title":"Ophthalmology"},{"key":"93962_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","volume":"118","author":"FG Holz","year":"2011","unstructured":"Holz, F. G. et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: The SUSTAIN study. Ophthalmology 118, 663\u2013671 (2011).","journal-title":"Ophthalmology"},{"key":"93962_CR28","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.cell.2011.08.039","volume":"146","author":"M Potente","year":"2011","unstructured":"Potente, M., Gerhardt, H. & Carmeliet, P. Basic and therapeutic aspects of angiogenesis. Cell 146, 873\u2013887 (2011).","journal-title":"Cell"},{"key":"93962_CR29","doi-asserted-by":"crossref","unstructured":"Miere, A. et al. Vascular remodeling of choroidal neovascularization after anti-vascular endothelial growth factor therapy visualized on optical coherence tomography angiography. Retina 39, 548\u2013557 (2019).","DOI":"10.1097\/IAE.0000000000001964"},{"key":"93962_CR30","doi-asserted-by":"publisher","first-page":"e000244","DOI":"10.1136\/bmjophth-2018-000244","volume":"4","author":"L Faes","year":"2019","unstructured":"Faes, L. et al. Effect of total anti-VEGF treatment exposure on patterns of choroidal neovascularisation assessed by optical coherence tomography angiography in age-related macular degeneration: A retrospective case series. BMJ Open Ophthalmol. 4, e000244 (2019).","journal-title":"BMJ Open Ophthalmol."},{"key":"93962_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ajo.2015.04.012","volume":"160","author":"RF Spaide","year":"2015","unstructured":"Spaide, R. F. Optical coherence tomography angiography signs of vascular abnormalization with antiangiogenic therapy for choroidal neovascularization. Am. J. Ophthalmol. 160, 6\u201316 (2015).","journal-title":"Am. J. Ophthalmol."},{"key":"93962_CR32","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00417-006-0516-y","volume":"245","author":"A Reichenbach","year":"2007","unstructured":"Reichenbach, A. et al. M\u00fcller cells as players in retinal degeneration and edema. Graefes Arch. Clin. Exp. Ophthalmol. 245, 627\u2013636 (2007).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"Pt 2","key":"93962_CR33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/eye.1990.46","volume":"4","author":"MF Marmor","year":"1990","unstructured":"Marmor, M. F. Control of subretinal fluid: Experimental and clinical studies. Eye (Lond.) 4(Pt 2), 340\u2013344 (1990).","journal-title":"Eye (Lond.)"},{"key":"93962_CR34","first-page":"2437","volume":"260","author":"KB Freund","year":"2022","unstructured":"Freund, K. B. et al. Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: Post hoc analysis of HARBOR. Graefes Arch. Clin. Exp. Ophthalmol. 260, 2437\u20132447 (2022).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"93962_CR35","doi-asserted-by":"publisher","first-page":"5040","DOI":"10.1167\/iovs.15-16494","volume":"56","author":"B Chae","year":"2015","unstructured":"Chae, B. et al. Baseline predictors for good versus poor visual outcomes in the treatment of neovascular age-related macular degeneration with intravitreal anti-VEGF therapy. Invest. Ophthalmol. Vis. Sci. 56, 5040\u20135047 (2015).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"93962_CR36","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3390\/jcm4071380","volume":"4","author":"S Mrejen","year":"2015","unstructured":"Mrejen, S. et al. Long-Term visual outcomes for a treat and extend anti-vascular endothelial growth factor regimen in eyes with neovascular age-related macular degeneration. J. Clin. Med. 4, 1380\u20131402 (2015).","journal-title":"J. Clin. Med."},{"key":"93962_CR37","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/s41433-022-02231-y","volume":"37","author":"T Mathis","year":"2023","unstructured":"Mathis, T. et al. Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes. Eye (Lond.)  37, 1758\u20131765 (2023).","journal-title":"Eye (Lond.)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93962-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93962-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93962-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T16:44:35Z","timestamp":1741970675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93962-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["93962"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-93962-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8911"}}